quality
CTNJ: OP-ED | Legislators Hear How RI Saved 2 Hospitals From Private Equity, Other Solutions to High Insurance Premiums
On Friday, in a forum sponsored by state Rep. Kerry Wood, six national and local experts gave legislators specific policy tools to help with health care market consolidation and rising drug prices that are driving up health insurance premiums. Legislators also got specific tools used by Rhode Island to avoid private equity abuses experienced in…
Read MoreCT residents over twice as likely to die of opioid or other drug poisoning than from alcohol
Connecticut ranked 17th lowest among states in alcohol-related deaths per capita, but seventh highest in opioid-related deaths in 2019, based on an analysis of data from SHADAC’s State Health Access Data Assistance Center. That year, Connecticut residents were 245% more likely to die from an opioid or other drug poisoning than from alcohol. (Opioid or…
Read MoreCTNJ OP-ED | Congress Wants to Lower Drug Prices to Fund Important Priorities
Economists argue that rising healthcare costs crowd out resources for other societal priorities such as education, infrastructure, climate change, and housing. It makes sense in theory but, until lately, it seemed a bit abstract. But right now, Congress and the administration are making the point in very real terms. Policymakers want to make big investments…
Read MoreRoom for improvement on CT health risks
Download the report Connecticut adults’ health risks are largely similar to the US average, but that’s not great news. According to the latest CDC survey of American adults, Connecticut ranked better than other Americans on most health risks in 2019. In most cases, we are only slightly healthier. We did exceed the US average in…
Read MoreNew healthy aging data report finds CT growing older in every community
Connecticut is the 7th oldest state in the country, according to a new analysis by UConn Boston and Tufts Health Plan Foundation, with 23% of state residents over age 60. The challenges of aging are not evenly spread across the state. Visit the site to see how seniors in your town/city compare to the state…
Read MoreCTNJ: Insulin – Once a Gift, Now Serving Greed
Today is the hundredth anniversary of the discovery of insulin. Diabetes affects about 367,000 adults in Connecticut and that number is rising. Before the 1920s, a diabetes diagnosis was a death sentence. The discovery of insulin allowed people with diabetes to live their lives. Until the 1970s insulin was affordable, but it’s now so costly…
Read MoreCT remains behind surrounding states in public health support
According to a new analysis by SHADAC, Connecticut remains behind our neighboring states in per person spending on public health. The pandemic has spotlighted the critical roles of public health including emergency preparedness, disease prevention, population health monitoring, and health promotion. Public health has been responsible for most of the increases in life expectancy in…
Read MoreOHS committee considering dumbing down successful PCMH standards
Among other troubling plans, the Office of Health Strategy’s Primary Care Subgroup is considering four options to certify high-performing primary care practices for higher levels of reimbursement. The committee is deciding how to double spending on primary care while simultaneously capping healthcare cost growth. At their meeting this week, the committee of mainly primary care…
Read MoreVery helpful data Roadmap to promote health equity in CT
While residents of Connecticut’s minority communities face significant disparities in health outcomes compared to white state residents, there has been no consistency or standardization of Race, Ethnicity and Language (REL) data collection. A new state law requires, among other things, that providers and state entities collect REL data using standard categories. A new report from…
Read MoreOP-ED | Controversial New Alzheimer’s Drug Could Break the Bank
Alzheimer’s disease affects six million Americans, stealing memories years before it takes lives. Aduhelm, the first drug intended to treat the Alzheimer’s disease process rather than symptoms, was highly anticipated by patients and families. But it has disappointed on many levels. It isn’t clear that it actually helps patients and troubling side effects are common.…
Read More